Company news
Camp4 Therapeutics Corporation (NASDAQ:CAMP) news
Camp4 Therapeutics Corporation news releases on 6ix. Latest, Sep 10, 2026: CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human…
Press releases & updates
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
September 10, 2026
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
September 8, 2026
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
August 13, 2026
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
August 4, 2026
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
July 27, 2026
CalAmp Expands Remote Monitoring Support for Modbus-Enabled Specialty Equipment
July 16, 2026
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
May 14, 2026
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
May 7, 2026
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
April 28, 2026
Calamos Brings Award-Winning Autocallable Income ETF Strategy to Global Investors with Launch of World's First Autocallable UCITS ETF
April 27, 2026
CAMP4 Appoints Michael MacLean to its Board of Directors
March 24, 2026
CAMP4 to Participate in Upcoming Investor Conferences
March 6, 2026
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
March 5, 2026
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
December 18, 2025
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
December 18, 2025
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2025
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
November 6, 2025
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
October 1, 2025
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
September 10, 2025
eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors
August 19, 2025
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
August 14, 2025
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
May 16, 2025
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
May 13, 2025
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
April 28, 2025
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
March 27, 2025
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors
March 18, 2025